Literature DB >> 1560265

Intracerebral (parenchymal) infusion of methotrexate: report of a case.

K A Page1, H Vogel, D S Horoupian.   

Abstract

This report describes the neuropathological findings in a 32 year old woman with acute myelogenous leukemia (AML) and central nervous system (CNS) involvement, who received a total of 48 mg of methotrexate (MTX) intended to be delivered to the ventricle. At autopsy, the tip of the infusion catheter was found to have been inadvertently placed in the left basal ganglia. The delivery of the MTX at that site caused white matter lesions characteristic of those previously reported in MTX encephalopathy following diverse modes of administration. This case is unusual in that there was the direct infusion of MTX into cerebral parenchyma, circumventing both the blood:brain and cerebrospinal fluid:brain barriers. Axonal abnormalities were widespread in the MTX-infused tissue, frequently but not always accompanied by myelin loss. Since radiation therapy had not been employed, this case permitted the assessment of pathologic changes largely attributable to MTX.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560265     DOI: 10.1007/bf00172670

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

1.  Pathologic findings in brain tumors treated with local methotrexate.

Authors:  S R Weiss; R Raskind
Journal:  Int Surg       Date:  1969-10

2.  Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia.

Authors:  W A Bleyer; J C Drake; B A Chabner
Journal:  N Engl J Med       Date:  1973-10-11       Impact factor: 91.245

3.  Leukoencephalopathy following the administration of methotrexate into the cerebrospinal fluid in the treatment of primary brain tumors.

Authors:  H Norrell; C B Wilson; D E Slagel; D B Clark
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

4.  Brain tumor chemotherapy with intrathecal methotrexate.

Authors:  C B Wilson; H A Norrell
Journal:  Cancer       Date:  1969-05       Impact factor: 6.860

Review 5.  Neurological complications of antineoplastic therapy.

Authors:  W R Shapiro; D F Young
Journal:  Acta Neurol Scand Suppl       Date:  1984

6.  Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy.

Authors:  L M DeAngelis; J Yahalom; M H Heinemann; C Cirrincione; H T Thaler; G Krol
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

7.  Successful non-neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine, and BCNU protocol (DEMOB).

Authors:  I J Cohen; R Vogel; S Matz; R Weitz; C Mor; S Stern; R Zaizov
Journal:  Cancer       Date:  1986-01-01       Impact factor: 6.860

8.  Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography.

Authors:  S A Grossman; D L Trump; D C Chen; G Thompson; E E Camargo
Journal:  Am J Med       Date:  1982-11       Impact factor: 4.965

Review 9.  Central nervous system pharmacology of antileukemic drugs.

Authors:  F M Balis; D G Poplack
Journal:  Am J Pediatr Hematol Oncol       Date:  1989

Review 10.  The role of chemotherapy in the treatment of gliomas in adults.

Authors:  D J Stewart
Journal:  Cancer Treat Rev       Date:  1989-09       Impact factor: 12.111

View more
  1 in total

1.  In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors.

Authors:  M Yamada; H Nakagawa; M Fukushima; K Shimizu; T Hayakawa; K Ikenaka
Journal:  J Neurooncol       Date:  1998-04       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.